3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 来源：新浪证券-红岸工作室 2月27日，金凯生科跌1.85%，成交额1.40亿元，换手率6.30%，总市值47.24亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 区间今日近3日近5日近10日近20日主力净流入-1575.73万-2528.60万-2748.99万-9459.02万-1.06亿 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来 ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant project involving the production of intermediates for Semaglutide oral formulations, which is part of its fundraising projects [2][3]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 12, the company's stock price decreased by 0.21%, with a trading volume of 93.35 million yuan and a turnover rate of 4.24%, resulting in a total market capitalization of 4.659 billion yuan [1]. - The stock has seen a net outflow of 4.177 million yuan from major investors today, with a ranking of 31 out of 52 in its industry [5][6].

Group 1 - China's January CPI increased by 0.2% year-on-year, which is lower than expected [1] - The A-share market showed mixed results, with the Shanghai Composite Index rising by 0.09% to 4131.99 points, while the Shenzhen Component Index fell by 0.35% and the ChiNext Index dropped by 1.08% [1] - The total market turnover was 2 trillion yuan, a decrease of 123.7 billion yuan compared to the previous trading day, with over 3200 stocks declining [1] Group 2 - The glass fiber sector experienced a surge, with leading companies like Guangyuan New Materials and International Composite raising prices for electronic fabrics, resulting in stocks like International Composite and China Jushi hitting the daily limit [1] - The small metals sector also performed well, with multiple stocks such as Zhongtung High-tech reaching the daily limit [1] - The phosphate chemical and fertilizer sectors saw gains, with Jinzhengda hitting the daily limit [1] Group 3 - The lithium mining, fluorochemical, and steel sectors had notable increases [1] - Conversely, sectors such as cultural media, film concepts, AI corpus, and Sora concepts saw declines, with stocks like Hengdian Film and Zhejiang Culture Industry hitting the daily limit [1] - The tourism sector fell, with Haikan Co. dropping over 11%, and the cultivated diamond sector experienced widespread declines, led by Sifangda [1]

市 场 研 究 [Table_Title] 万联晨会 [Table_MeetReportDate] 2026 年 02 月 09 日 星期一 [Table_Summary] 概览 3096 核心观点 【市场回顾】 上周五，A 股低开后震荡上行，尾盘有所回落，截至收盘，上证指数 收跌 0.25%，报 4065.58 点，深证成指跌 0.33%，创业板指跌 0.73%。 沪深两市 A 股成交额约 2.15 万亿元人民币，超 2500 股上涨。申万行 业方面，石油石化、基础化工行业领涨，食品饮料行业领跌；概念板 块方面，氟化工概念、染料概念涨幅居前。港股方面，香港恒生指数 收跌 1.21%，恒生科技指数跌 1.11%。美国三大股指全线收涨，道指 涨 2.47%，报 50115.67 点，创历史新高，标普 500 指数涨 1.97%，纳 指涨 2.18%。欧洲股市全线上涨，亚太股市多数下跌。 【重要新闻】 【李强主持召开国务院第十次全体会议，讨论政府工作报告稿和"十 五五"规划纲要草案稿】国务院总理李强 2 月 6 日主持召开国务院第 十次全体会议，讨论拟提请十四届全国人大四次会议审议的政府工作 报告稿和"十五五"规 ...

Group 1 - The top trending stocks in A-shares include Xiexin Integrated, Sanyan Co., Shenjian Co., Data Port, Juliy Suoj, Hangdian Co., Galaxy Electronics, Yongtai Technology, Intercontinental Oil and Gas, and Wuzhou New Spring [1][2] - Xiexin Integrated's rise is attributed to significant breakthroughs in perovskite tandem battery technology, achieving a certification efficiency of 33.31%, and its strategic focus on space photovoltaic equipment development [3] - Sanyan Co. is gaining attention due to a proposed investment of approximately 7.2 billion yuan from Anhui State-owned Wanhui Group, which alleviates uncertainties from its restructuring process [3] Group 2 - Shenjian Co. benefits from the growing commercial aerospace sector, with its subsidiary being a key supplier for major rocket components, enhancing investor interest [4] - Data Port's focus is driven by the "East Data West Calculation" strategy, which supports the data center industry, alongside increasing demand for AI and computing power [4] - Juliy Suoj is recognized as a core supplier in the commercial aerospace and deep-sea equipment sectors, with significant orders extending to 2026 [5] Group 3 - Hangdian Co. is experiencing growth due to multiple favorable themes and national investment plans in the power grid sector, with its business covering ultra-high voltage and optical communication [5] - Galaxy Electronics is gaining traction due to its involvement in military information technology and commercial aerospace, with a significant reduction in losses reported [6] - Yongtai Technology's partnership with CATL is a key catalyst for its market interest, as it aims to deepen integration within the new energy supply chain [6]

Market Overview - The A-share market is experiencing fluctuations, with the three major indices continuing their downward trend [1] - The Shanghai Composite Index closed at 4065.58, down 0.25%, while the Shenzhen Component Index fell 0.33% to 13906.73 [2] Sector Performance - The top-performing sectors include: - Oil and Petrochemicals: +2.55% - Basic Chemicals: +2.05% - Electric Equipment: +1.27% - Textiles and Apparel: +0.88% - Light Industry Manufacturing: +0.66% [3] - The underperforming sectors are: - Food and Beverage: -1.86% - Defense and Military: -1.66% - Social Services: -1.37% - Communication: -1.26% - Beauty and Personal Care: -1.20% [3] Future Outlook - The market showed volatility with a low opening followed by a brief recovery, but ultimately closed lower, with the ChiNext Index leading the decline [4] - Chemical sectors showed strength, while consumer sectors like liquor and tourism faced significant declines [4] - The report indicates a shift in investment focus towards a dual-driven model of manufacturing and consumption, with manufacturing sectors entering a profit realization phase and consumer sectors poised for potential recovery as valuations are at historical lows [6]

Group 1 - The core viewpoint of the news is that the prices of refrigerants R404A and R507 are increasing, driven by demand from overseas markets, particularly as A5 countries approach the end of their quota baseline year, leading to a surge in imports of high GWP refrigerants and boosting exports from China [1] - The external trade price of refrigerants has risen to approximately 35,000 yuan per ton, while domestic prices have increased to around 49,000 yuan per ton, indicating a growing market atmosphere as companies actively raise prices [1] - The overall inventory in the industry is at a near two-year low, combined with production constraints due to quota limitations and high industry concentration, resulting in widespread reluctance among companies to sell, which further supports price increases [1] Group 2 - The CSI Sub-Industry Chemical Theme Index (000813) has seen a strong increase of 1.86%, with constituent stocks such as Haohua Technology rising by 5.27%, Yara International by 4.68%, and Boyuan Chemical by 4.26% [1] - The Chemical ETF (159870) has risen by 2.10%, with the latest price reported at 0.88 yuan [1] - As of December 31, 2025, the top ten weighted stocks in the CSI Sub-Industry Chemical Theme Index include Wanhua Chemical, Salt Lake Shares, and others, collectively accounting for 45.31% of the index [2]

Core Viewpoint - The company JinKai Life Science has shown significant growth in revenue and profit, driven by its CDMO services for pharmaceutical companies and benefiting from the depreciation of the RMB [4][8]. Group 1: Company Overview - JinKai Life Science Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009, with its IPO on August 3, 2023 [8]. - The company specializes in providing custom development and manufacturing services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [2][8]. - The main revenue sources include 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96% [8]. - The net profit attributable to the parent company was 103 million yuan, showing a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The company is involved in various concepts including CRO, weight loss drugs, Alzheimer's-related services, and fluorochemical products [2][3]. - The stock has seen a recent increase in trading volume and interest, with a significant net inflow of 8.75 million yuan on the latest trading day [5][6].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business involves offering small molecule CDMO services to global life science clients, assisting in the synthesis process of innovative drug development [8]. - The company's revenue composition includes 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a significant increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Market Position - As of December 19, the number of shareholders in the company was 14,300, a decrease of 0.54% from the previous period, while the average circulating shares per person increased by 0.54% to 3,974 shares [8]. - The company benefits from a 61.18% overseas revenue share, aided by the depreciation of the Chinese yuan [4]. Product and Service Development - The company is involved in the development of intermediates for drugs related to Alzheimer's disease and has capabilities in producing specialized fluorinated agents [3][4]. - The company’s listed fundraising projects include the "Pharmaceutical Intermediate Project" and a project for producing 190 tons of high-end pharmaceutical products, which includes intermediates for Semaglutide oral formulations [2][3].

Group 1 - The fluorochemical sector experienced a decline of 1.61%, ranking among the top losers in concept sectors, with major declines seen in companies like Hongyuan Pharmaceutical, Duofluoride, and Shenzhen New Star [1] - The top gainers in the fluorochemical sector included Hainan Mining, Shangwei Co., and Ankao Intelligent Electric, with respective increases of 3.09%, 3.06%, and 1.36% [1] - The overall market saw significant net outflows from the fluorochemical sector, totaling 4.951 billion yuan, with 50 stocks experiencing net outflows, and 10 stocks seeing outflows exceeding 100 million yuan [1] Group 2 - Duofluoride led the net outflow with 1.114 billion yuan, followed by Tianji Co., Tianqi Materials, and Nanda Optoelectronics with outflows of 1.045 billion yuan, 565 million yuan, and 382 million yuan respectively [1] - The stocks with the highest net inflows included Yuntianhua, Huabang Health, and Zhongmi Holdings, with net inflows of 123 million yuan, 2.05 million yuan, and 800,900 yuan respectively [1] - The fluorochemical sector's outflow leaderboard featured Duofluoride with a decline of 8.06%, Tianji Co. with a slight increase of 0.40%, and Tianqi Materials with a decrease of 3.80% [2]